The novel hydrogen-PT2385-silncARSR nanocomplex impairs tumor angiogenesis and mitochondrial activity in sunitinib-resistant renal cancer.
In a laboratory model, thus, the anti-angiogenic activity of PT2385 (HIF-2α inhibitor) was potentiated by H₂ and silncARSR significantly. The authors concluded that looking forward to future clinical translation, the therapeutic efficacy of this approach could be further enhanced through integration with…
Read Article